Functional and Structural Outcomes in Neovascular Age-related Macular Degeneration
Status:
Completed
Trial end date:
2017-11-09
Target enrollment:
Participant gender:
Summary
Several studies during the last years reported the involvement of anti-retinal autoantibodies
in ocular disorders, such as AMD. These studies support the growing evidence of an
immunological involvement in the pathogenesis of AMD. In the planned trial it is planned to
enroll 70 subjects, i.e. 50 subjects with neovascular AMD and 20 healthy volunteers. The
investigators will evaluate the change from Baseline (Visit 1) in BCVA score at Week 12
(visit 4) in the study eye of nAMD patients treated with Ranibizumab. Neovascular AMD
patients (group 1) will be accompanied for 6 months and blood samples will be collected at
baseline and monthly until Visit 7 for analysis of antibody profiles. Healthy volunteers
(group 2) will be enrolled and a blood sample will be collected once for analysis of antibody
profiles. Antibody profiles of all study participants will be analysed to address questions
as defined in the outcome measures.